News/Companies/EVOK

EVOK News

Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million

August 14, 2025Earnings

Evoke Pharma Q1 EPS $(0.51) Misses $(0.33) Estimate, Sales $3.08M Miss $3.32M Estimate

May 13, 2025

Evoke Pharma Q4 Sales $3.31M Beat $3.08M Estimate

March 13, 2025

Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025

December 19, 2024

Evoke Pharma Presents Additional GIMOTI Healthcare Utilization Data Focused On Gastroparesis Care Insights In Women At DDW 2024 Conference

May 16, 2024